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The aims of this phase I study were to establish the maximum tolerated dose, safety proﬁle and activity of liposomal
daunorubicin, DaunoXome (NeXstar Pharmaceuticals), in the treatment of metastatic breast cancer. DaunoXome was
administered intravenously over 2 h in 21 day cycles and doses were increased from 80 to 100, 120 and 150 mg m
2. Sixteen
patients were enrolled. A total of 70 cycles of DaunoXome were administered. The maximum tolerated dose was
120 mg m
2, the dose-limiting toxicity being prolonged grade 4 neutropenia or neutropenic pyrexia necessitating dose
reductions at 120 and 150 mg m
2. Asymptomatic cardiotoxicity was observed in three patients: grade 1 in one treated with a
cumulative dose of 800 mg m
2 and grade 2 in two, one who received a cumulative dose of 960 mg m
2 and the other a
cumulative dose of 600 mg m
2 with a previous neoadjuvant doxorubicin chemotherapy of 300 mg m
2. Tumour response was
evaluable in 15 patients, of whom two had objective responses, six had stable disease and seven had progressive disease. In
conclusion, DaunoXome is associated with mild, manageable toxicities and has anti-tumour activity in metastatic breast cancer.
The ﬁndings support further phase II evaluation of DaunoXome alone and in combination with other standard non-
anthracycline cytotoxic or novel targeted agents. Although the dose-limiting toxicity for DaunoXome was febrile neutropenia
at 120 mg m
2, we would recommend this dose for further evaluation, as the febrile neutropenia occurred after four or more
cycles in three of the four episodes seen, was short lived and uncomplicated.
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The anthracyclines, doxorubicin and epirubicin, used as single
agents or in combination regimens, are established as ﬁrst line
treatment in the management of locally advanced and metastatic
breast cancer (A’hern et al, 1993). The use of these drugs is,
however, limited by their acute toxicities and propensity to cause
cumulative cardiac damage (Buzdar et al, 1985). Liposomal encap-
sulation of anti-cancer drugs is a novel therapeutic strategy in the
management of patients with malignant disease (Langer, 1998).
Potential advantages of liposome-mediated drug delivery systems
include increased plasma drug concentrations, improved drug
delivery and tumour targeting, reduced toxicity and evidence of
increased efﬁcacy (Gabizon, 1992). These contentions are
supported by recent large phase II and III studies of Caelyx
TM
(pegylated stealth liposomal doxorubicin, Doxil, Sequus Pharma-
ceuticals, Menlo Park, CA, USA) in patients with solid tumours.
In a study of 71 patients with metastatic breast cancer the agent
was well tolerated with a reduction in alopecia, nausea and vomit-
ing, and neutropenic pyrexia compared to that expected from
conventional doxorubicin therapy. No signiﬁcant cardiotoxicity
was seen with the Caelyx
TM treatment. This improvement in toler-
ability was not at the expense of anti-tumour activity, the objective
response rate being 31% (Ranson et al, 1997). Furthermore,
Caelyx
TM has enhanced anti-tumour activity compared to conven-
tional doxorubicin in relapsed ovarian cancer and has been
demonstrated to be at least equivalent in efﬁcacy to topotecan
(Gordon et al, 2001).
Daunorubicin is an anthracycline which has been used in the
treatment of leukaemias since the 1960s. Daunorubicin has been
evaluated in the treatment of a wide variety of solid tumours with
objective responses being seen in relatively large phase II studies of
soft tissue sarcoma and colorectal cancer. Tumour responses have
also been noted in non-small cell and small cell lung, renal and
prostate cancer, choriocarcinoma and neuroblastoma, and with
intravesical treatment of bladder cancer. In the 1980s, development
of daunorubicin in the treatment of solid tumours including breast
cancer was discontinued due to the tremendous number of anthra-
cycline analogues and anthracene derivatives (e.g. mitoxantrone)
being evaluated (Harvey et al, 1984; Von Hoff, 1984).
DaunoXome is a liposome-encapsulated form of daunorubicin
in which the anthracycline has been entrapped in small unilamellar
vesicles (diameter: 40–80 nm, mean: 45 nm) composed of a 2:1
molar ratio of highly puriﬁed distearoyl phosphatidylcholine
(DSPC) and cholesterol. The pharmacokinetic proﬁle of Dauno-
Xome is different from conventional daunorubicin with a 36-fold
increase in the area under the plasma concentration curve and a
ﬁrst phase elimination half-life of 5.3 to 8.3 h (Rahman et al,
1984a; Forssen and Ross, 1994; Gill et al, 1995; Bellott et al,
2001). In vivo experiments indicate increased uptake of dauno-
Xome in tumour tissue at 24 h compared to conventional daunor-
ubicin (Forssen et al, 1992, 1996). DaunoXome (NeXstar
Pharmaceuticals) is licensed for the treatment of AIDS-related
Kaposi’s sarcoma (Gill et al, 1995, 1996). Given the early encoura-
ging anti-tumour activity of daunorubicin, DaunoXome was
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phase II dose for patients who had received prior chemotherapy
was found to be 100 mg m
2 and in chemotherapy-naı ¨ve indivi-
duals, 120 mg m
2 (Guaglianone et al, 1994). In a study in
relapsed or refractory lymphomas, one complete and two partial
responses were seen in nine patients treated at 120 mg m
2
(Richardson et al, 1997). Apart from signiﬁcant neutropenia (grade
3 or higher) seen at doses of 80 mg m
2 or above, the agent appears
well tolerated with a reduction in alopecia, nausea and vomiting
and perhaps also cardiotoxicity compared to standard anthracy-
clines (Guaglianone et al, 1994; Richardson et al, 1997).
There is little data on the use of daunorubicin in the treatment
of breast cancer. Van Hoff (1984) identiﬁed only four patients with
breast cancer treated in early phase studies in whom no anti-
tumour activity was observed. Subsequently clear evidence emerged
that not all anthracyclines had equal efﬁcacy in metastatic breast
cancer. For example idarubicin, esorubicin and carcinomycin had
inferior response rates to doxorubicin and/or epirubicin (Rozenc-
weig et al, 1984; Bonfante et al, 1986; Lopez et al, 1989).
However, in vitro studies indicate that daunorubicin has equivalent
cytotoxicity to doxorubicin in breast adenocarcinoma lines (Wiles
et al, 1997). Furthermore, a preliminary report presented by
Hupperets et al (1996) indicated that DaunoXome 100 mg m
2
every 21 days for up to 24 weeks had encouraging single agent
anti-tumour activity in metastatic breast cancer with objective
tumour responses in three and stable disease in seven out of 11
treated patients (Anonymous, 1996). This evidence was deemed
appropriate to justify a phase I study of DaunoXome in an anthra-
cycline-naı ¨ve population presenting with metastatic breast cancer.
PATIENTS AND METHODS
Study design
A phase I dose-escalating study was developed to establish the
MTD of, and to obtain preliminary efﬁcacy and tolerability data
for, DaunoXome in the treatment of anthracycline-naı ¨ve patients
with advanced breast cancer. A starting dose of 80 mg m
2 was
chosen because of the signiﬁcant neutropenia reported at this level
in previous work (Guaglianone et al, 1994).
Cohorts of at least three patients were to be treated at each dose
level. The planned dose escalation was from 80 to 100, 120, 150
and 180 mg m
2. No intra-patient dose escalation was permitted.
For safety reasons, the next dose level was not opened until the
ﬁnal patient in a given cohort had been observed for 21 days.
The dose-limiting toxicities (DLT) were deﬁned as (i) any grade
3 or 4 non-haematologic drug-induced toxicity excluding alopecia,
nausea or vomiting, (ii) any haematologic toxicity necessitating a
dose reduction and (iii) any drug-induced adverse event that
warranted removal of the patient from the study. If a DLT was
encountered at any dose level, a further three patients were
enrolled at that dose. If a DLT occurred in two patients then that
dose level was declared the maximum tolerated dose (MTD) and
no further dose escalations occurred.
Eligibility criteria
Patients with evaluable, histologically or cytologically conﬁrmed,
metastatic breast cancer were eligible for the study. Prior non-
anthracycline based chemotherapy, hormonal manipulation, immu-
notherapy and radiotherapy were permitted. Adjuvant or
neoadjuvant anthracycline-based chemotherapy was allowed
provided that the time to relapse after completion of chemotherapy
was 46 months, the cumulative doxorubicin dose was
4300 mg m
2 and epirubicin 4400 mg m
2. Normal cardiac func-
tion, with left ventricular ejection fraction (LVEF) 450% as
assessed by echocardiography was essential. Other inclusion criteria
included Eastern Cooperative Oncology Group performance status
of 42, life expectancy of at least 12 weeks, adequate bone marrow
function (total white cell count 43610
9 per l, absolute neutrophil
count 41.5610
9 per l, haemoglobin count 49gd l
71, and plate-
let count 4100610
9 per l), adequate hepatic function (total
bilirubin concentration 51.56ULN, transaminases 536ULN,
unless due to liver metastases), adequate renal function (serum
creatinine in the normal range) and no other primary cancer with-
in 5 years (except basal cell skin carcinoma or carcinoma-in-situ of
the cervix). Exclusion criteria included prior bone marrow trans-
plantation, CNS involvement, concomitant radiotherapy, a
history of cardiac disease or uncontrolled hypertension. Patients
gave written informed consent to participation in the study, which
was approved by the local Ethics Committee.
Study treatment
DaunoXome was administered on day 1 of a 21 day cycle as a 2 h
infusion in the out-patient department. Prophylactic anti-emetic
treatment with 5HT-antagonists was not given. In the event of
drug hypersensitivity, the infusion was continued with oral antihis-
tamines for a mild reaction, and the rate of infusion could be
slowed based on symptoms (grade 1). For a moderate or severe
reaction (grades 2 or 3), the infusion was stopped, intravenous
antihistamine and dexamethasone given, and the infusion restarted
at a slower rate with premedication with antihistamine and steroids
on further cycles. A maximum of eight cycles of DaunoXome could
be administered. Prophylactic use of colony-stimulating growth
factors was not permitted.
On-study investigations
Pre-treatment evaluation included full blood count, renal, liver and
bone biochemistry, ECG, echocardiography and establishment of
evaluable disease sites by physical examination and/or radiology.
On-treatment evaluation included a weekly full blood count, renal,
liver and bone biochemistry proﬁle prior to each treatment, echo-
cardiography after four cycles (after two cycles if the patient had
received prior adjuvant anthracycline-based therapy) and subse-
quently after every two cycles until the end of treatment.
Dose modiﬁcation was carried out in the event of haematologi-
cal or other toxicities as deﬁned by the NCIC CTG Expanded
Common Toxicity Criteria. If the full blood count was not
adequate on day 21 (ANC 41.5610
9 per l or platelets
4100610
9 per l), the treatment was deferred by 7 days. For grade
4 neutropenia persisting for 47 days, a dose delay 42 weeks,
grade 4 thrombocytopenia or an episode of thrombocytopenic
bleeding, the dose was reduced by 20 mg m
2 or one dose level.
In the event of grade 3 or 4 non-haematological toxicity (except
for alopecia, and nausea and vomiting subsequently controlled by
anti-emetics) the dose was again reduced by 20 mg m
2 or one dose
level.
In patients with easily accessible lesions, biopsies were
performed 24 h after administration of the ﬁrst cycle of Dauno-
Xome to look for evidence of uptake of the agent into tumour
tissue using confocal laser microscopy.
Response evaluation
Tumour response was formally assessed after every two cycles of
chemotherapy in accordance with WHO guidelines. A complete
response was deﬁned as the complete resolution of all disease. A
partial response was deﬁned as a reduction of 50% or more in
the sum of the bi-dimensional mass measurements. Both responses
required a duration of more than 4 weeks with a conﬁrmatory
physical examination and/or radiological assessment. Stable disease
was deﬁned as less than 50% reduction in the disease and progres-
sive disease was deﬁned as 525% increase in the sum of the bi-
dimensional tumour measurements. Duration of response was
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time of clinical evidence of disease progression.
RESULTS
Patient characteristics
Sixteen patients were enrolled onto the study. The median age was
51 years (range 34 to 68 years). Twelve of the 16 patients had visc-
eral disease. The lungs, liver and bone were the most common sites
of metastasis. Only one patient had not received prior treatment
for breast cancer. Twelve patients had received adjuvant radiother-
apy and eight had received adjuvant chemotherapy of which one
had been anthracycline containing. Twelve patients had received
prior hormonal therapy and in seven patients, second line hormo-
nal therapy had been commenced at the time of diagnosis of
metastatic disease. Additional patient characteristics are listed in
Table 1. All patients were evaluable for toxicity. Altogether 70
cycles of treatment were given. The median number of cycles of
DaunoXome administered was six per patient (range 1–8).
Considering the 120 and 150 mg m
2 dose levels of DaunoXome
only, the mean number of cycles administered remained high at
5.75 per patient.
Haematological toxicity
Grade 4 neutropenia was encountered in 11, and grade 3 in three
patients (Table 2). In the majority of cases the neutropenia was
experienced during the ﬁrst cycle of therapy without obvious
cumulative myelosuppression. Neutropenia was complicated by a
total of four febrile episodes affecting three patients. The febrile
episodes occurred during cycle 1 of level 3 treatment in one patient
only. This patient had a further febrile episode on the sixth cycle at
level 2. The other febrile episodes occurred on the fourth cycle in
one patient on level 4 and after six cycles in another on level 3. All
episodes responded promptly to intravenous antibiotics. Eight out
of the 70 cycles of chemotherapy were delayed due to neutropenia.
As a result of these complications, dose reductions were required
on ﬁve occasions (Table 3). No grade 3 or 4 anaemia was seen.
One patient experienced grade 3 thrombocytopenia but no
episodes of thrombocytopenic bleeding were seen. The haematolo-
gical toxicities deﬁned the MTD at 120 mg m
2 (Table 3).
Cardiotoxicity
Pretreatment echocardiographic assessment revealed gross cardiac
function to be normal in all patients with LVEF 450%. A signif-
icant asymptomatic change in cardiac function was seen in three
patients: One at dose level 4 had grade 1 cardiac toxicity with a
DaunoXome cumulative dose (CD) administered of 800 mg m
2.
An initial echocardiographic study revealed normal cardiac func-
tion but failed to give an accurate LVEF. She had subsequent
studies with MUGA scans, that revealed deterioration in LVEF
from 65 to 50% after six cycles of therapy. MUGA scans 1 and
3 months post-treatment revealed no further deterioration in
cardiac function with LVEF of 51% on both occasions. One
patient at dose level 2 with grade 2 cardiotoxicity received a
DaunoXome CD of 600 mg m
2 and had previously received a
doxorubicin CD of 300 mg m
2 in the adjuvant setting. Baseline
LVEF=75% was unchanged after two and four cycles of treatment
(74%) but fell to 46% after six cycles. Repeat studies 2, 5 and 8
months after the last administration of DaunoXome revealed no
further deterioration in cardiac function with LVEF readings of
48, 53 and 53% respectively. A further patient at dose level 3
received a cumulative dose of 960 mg m
2 and had a deterioration
in LVEF from 84 to 57% over eight cycles of treatment with no
further deterioration when evaluated 3 months later. She died 18
months after completion of DaunoXome therapy without any
history of a cardiac event.
Other non-haematological toxicity
No grade 3 or 4 non-haematological toxicity was seen (Table 2).
The most common non-haematological toxicity was alopecia with
seven of the 16 patients having some hair loss; this, however, was
usually minimal with only two patients having grade 2 alopecia.
Prophylactic anti-emetics with 5HT antagonists were not
prescribed and there was very little nausea and vomiting seen;
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Table 1 Summary of patient characteristics
Characteristic No. of patients
Age (years)
Median 51
Range 34–68
ECOG performance status
a
05
18
23
Number of metastatic sites
13
27
536
Prior treatment
None 1
Adjuvant radiotherapy 12
Adjuvant chemotherapy 8
b
Adjuvant hormonal treatment 12
Hormonal treatment for metastases 7
aECOG: Eastern Cooperative Oncology Group;
bOf which one was anthracycline-
containing.
Table 2 NCI–CTC toxicity by worst grade
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Nausea 2 5 – –
Vomiting 3 1 – –
Alopecia 5 2 – –
Neutropenia 1 1 3 11
Anaemia 3 4 – –
Thrombocytopenia 6 2 1 –
Hypersensitivity 3 2 – –
Cardiac impairment 1 2 – –
Fatigue 3 2 – –
Diarrhoea 1 – – –
Mucositis 2 1 – –
Table 3 Incidence of Grade 3 and 4 neutropenia, associated complica-
tions and dose reductions per treatment level
Treatment Dose No. of Grade Grade Dose
level (mg m
2) patients 3 4 Pyrexia reductions
18 0 4 2 1 0 0
2 100 4 0 3 0 0
3 120 6 1 5 3
a 2
4 150 2 0 2 1
b 3
aOne patient had an episode of neutropenic pyrexia after cycle 1 treatment. The
subsequent cycle was dose reduced to level 2. She had a further episode of neutro-
penic pyrexia after cycle 6. The second patient had an episode of neutropenic pyrexia
after cycle 6 treatment. Neither patient received further cycles of therapy.
bThe
patient affected had the pyrexial episode after cycle 4 treatment.
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and 2 vomiting. Five patients experienced a mild hypersensitivity
reaction during treatment, the most common symptom being the
onset of low back pain which was relieved by slowing the rate of
DaunoXome infusion.
Anti-tumour activity
Of the 15 patients evaluable for response, one achieved a complete
response, one had a partial response, six had stable disease and
seven had progressive disease. The overall median time to progres-
sion was 5 months (range 15–485+ days) which increased to 8.5
months (range 29–485+ days) at dose levels 3 and 4 (DaunoXome
120 and 150 mg m
2). The overall median survival was 13.75
months (range 18–705 days). In the patients treated at dose levels
3 and 4, the median survival was 19 months.
DISCUSSION
In keeping with the results of previous phase I and II studies in
solid tumours and lymphomas, and with the in vitro data, this
study indicates that DaunoXome is well tolerated and, at doses
5100 mg m
2, has anti-tumour activity in metastatic breast
cancer. The agent has a different toxicity proﬁle to conventional
anthra-cyclines and Caelyx
TM (Buzdar et al, 1985; A’hern et al,
1993; Ranson et al, 1997). Unlike conventional anthracyclines,
signiﬁcant alopecia was not observed and the patients did not
require prophylactic anti-emetics with 5HT antagonists, no grade
3 or 4 nausea or vomiting being seen. Plantar-palmar erythrody-
sesthesia, an epithelial toxicity observed in patients receiving
protracted infusions or repeated dose-intensive administration of
doxorubicin (Samuels et al, 1987; Bronchud et al, 1989), and
the dose-limiting side-effect of caelyxs
TM (Ranson et al, 1997),
was not observed with DaunoXome in this study. This difference
is most likely explained by the relatively protracted elimination
half-life of Caelyx
TM (half-life 448 h) compared with that of
DaunoXome (half-life 5.3–8.3 h).
Grade 4 neutropenia was documented in 11 patients although
febrile neutropenia only occurred in three, all of whom entered
the study at either the 120 or 150 mg m
2 dose levels. The
febrile episodes were short-lived and uncomplicated. Out of
the 70 cycles of chemotherapy delivered, only eight were delayed
due to neutropenia. Five dose reductions were necessitated
because of either protracted (47 days) or pyrexia associated
neutropenia, of which three were in the two patients initially
treated at the 150 mg m
2 dose level and the other two in
one patient treated initially at 120 mg m
2. These results indicate
that the MTD in patients with metastatic breast cancer, treated
without colony stimulating growth factor support, was Dauno-
Xome 120 mg m
2. As the pyrexial episodes were relatively
uncomplicated, we would recommend this dose for evaluation
in phase II studies. Other signiﬁcant haematological complica-
tions were rarely seen with only one patient having grade 3
thrombocytopenia.
The level of myelosuppression was higher than that seen for
Caelyx
TM in breast cancer in which, in the largest reported study,
no episodes of febrile neutropenia were seen (Ranson et al,
1997). This may in part be explained by the number of cycles
the patients received. In the Caelyx
TM study, a median of 3.6 cycles
were administered to each patient which was signiﬁcantly lower
than the six per patient treated with DaunoXome in this study.
Febrile neutropenia occurring in cycle 1 was seen in one patient
only. The other episodes occurred after four or more cycles of ther-
apy were given. Furthermore the mucocutaneous toxicity in the
Caelyx
TM study necessitated dose reductions and deferments, which
may make the rate of grade 3/4 myelosuppression seen in the
Caelyx
TM study, and hence associated febrile complications, rela-
tively lower.
Current recommendations indicate that CD of conventional
daunorubicin should not exceed 650 mg m
2 (Lenaz and Page,
1976). However the risk of cardiotoxicity falls if relatively low bolus
doses of any given anthracycline are used allowing higher CDs to
be administered (Sallan and Clavell, 1984). In animal models, the
cardiotoxic effects of anthracyclines are ameliorated when adminis-
tered in liposomal formulations (Rahman et al, 1984b). In this
study, grade I cardiotoxicity was seen in one patient at level 4
and grade II in one patient at level 3, who received a Dauno-Xome
CD of 800 and 960 mg m
2 respectively. These patients did not have
any obvious risk factors for developing cardiotoxicity and they had
not received prior anthracycline chemotherapy. A further patient
with grade 2 cardiotoxicity received daunoXome 100 mg m
2 to a
CD of 600 mg m
2 but had received doxorubicin CD of
300 mg m
2 in her combination adjuvant chemotherapy regimen.
None of the patients required treatment. The reduction in LVEF
stopped after completion of chemotherapy with no further dete-
rioration in function either symptomatically or on imaging for
up to 18 months following the last administration of DaunoXome.
Therefore evidence of subclinical cardiotoxicity developed at CD
levels one would anticipate might lead to symptomatic cardiac
problems using conventional daunorubicin. A number of recent
studies evaluating DaunoXome in the treatment of lymphomas
and solid tumours, and using similar doses to those reported here,
have reported an absence of cardiac side-effects (Fossa et al, 1998;
Richardson et al, 1997).
That DaunoXome may be less cardiotoxic than conventional
daunorubicin is supported by the recent observations for Myocet
which encapsulates doxorubicin in a conventional liposome (The
Liposome Company, Elan Corporation). Myocet has been shown
to improve the therapeutic index of doxorubicin by signiﬁcantly
reducing cardiotoxicity, allowing higher CD of doxorubicin to be
administered (Batist et al, 2001). Further work would be required
to deﬁnitively establish the CD for DaunoXome infusion bolus
doses 5100 mg m
2 that should not be exceeded in order to
prevent symptomatic cardiac toxicity. This is potentially of great
importance given the toxicity proﬁle of the recently developed
therapeutic anti-HER2/neu monoclonal antibody, Herceptin, when
used in combination with the conventional anthracycline doxoru-
bicin. Despite enhancing the anti-tumour efﬁcacy of cytotoxic
agents and prolonging survival, signiﬁcantly increased cardiac toxi-
city was seen in the anthracycline containing arm of the study
(Slamon et al, 2001). Combination of herceptin with liposomal
anthracyclines may represent a strategy to overcome this problem.
The study conﬁrms that DaunoXome does have anti-tumour
activity in metastatic breast cancer. A further recent study in meta-
static breast cancer has reported objective tumour responses in
three of nine patients treated with the agent (Darskaia et al,
1999). Combining the results of this study with the two published
reports DaunoXome has shown objective responses in eight out of
35 (23%) evaluable patients (Anonymous, 1996; Darskaia et al,
1999). The response rate for this relatively non-toxic anthracycline
based therapy must be taken in context with those reported for
single-agent doxorubicin which vary from 30–34% in recent
randomised phase III studies (Henderson et al, 1989; Sledge et
al, 1997; Chan et al, 1999; Norris et al, 2000). The overall time
to tumour progression of 5 months (8.5 months in those patients
treated at 120 and 150 mg m
2) and median survival of 13.75
months are in keeping with the results reported for large rando-
mised studies of doxorubicin when used alone or as part of a
combination regimen in the treatment of symptomatic relapsed
breast cancer (Norris et al, 2000).
A series of phase I studies have evaluated the combination of
Caelyx
TM with the novel agents gemcitabine, vinorelbine and pacli-
taxel with encouraging response rates and acceptable toxicity
proﬁles (Burstein et al, 1999; Schwonzen et al, 2000; Rivera et al,
2001). In a recent phase I study, DaunoXome was substituted for
doxorubicin in the conventional CHOP regimen to treat patients
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partial responses were seen in 44% of treated patients and the MTD
was 70–80 mg m
2 depending on the population treated (Flinn et al,
2000). These results indicate the potential for inclusion of DaunoX-
ome in combination regimens for metastatic breast cancer.
The anti-tumour efﬁcacy and tolerability of DaunoXome
demonstrated here make it eminently suitable for the treatment
of metastatic breast cancer, where agents with minimal toxicity
are often sought, particularly in elderly, frail patients. A rando-
mised phase II study comparing DaunoXome with conventional
doxorubicin has been proposed to compare anti-tumour activity,
time to tumour progression, survival and quality of life. The agent
also requires evaluation in phase II combination studies with
conventional cytotoxic agents and novel targeted therapies such
as Herceptin.
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